Q2 2026 saw 5.7% revenue growth to $5.3B, with net income up 15.5% to $561M and EPS at $1.24. AIS and PDx segments drove gains, while PCS declined. Major acquisitions, tariff refunds, and share repurchases shaped results, with strong liquidity and ongoing macro risks.Original document: GE HealthCar…
Q2 2026 saw 5.7% revenue growth to $5.3B, with net income up 15.5% to $561M and EPS at $1.24. AIS and PDx segments drove gains, while PCS declined. Major acquisitions, tariff refunds, and share repurchases shaped results, with strong liquidity and ongoing macro risks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
